A new systematic review and meta-analysis published in BMC Cancer has now brought the weight of all available evidence to bear on that question, and its conclusions are both reassuring and subtly intriguing. Led by Mohammad Amouzadeh-Lichahi, Maryam Jafari, Nazila Sattari, Sara Zamani, Negin Letafatkar and Shahriar Ghodous of Guilan University of Medical Sciences in Rasht, Iran, the research team systematically searched PubMed, Scopus and Embase for observational studies published up to July 2026. Their exhaustive sweep of the literature identified twenty-seven reports that met their rigorous inclusion criteria, covering the use of oral contraceptive pills, menopausal hormone therapy, estrogen therapy alone, and combined estrogen–progestin therapy in relation to pancreatic cancer risk. By pooling adjusted effect estimates across studies with random-effects models, the team aimed to produce the most definitive statistical picture to date of how these hormonal exposures relate to one of oncology’s deadliest cancers.

The methodological machinery behind the analysis was considerable. The researchers followed PRISMA reporting guidelines and evaluated study quality using the Newcastle–Ottawa Scale, while the certainty of the resulting evidence was graded with the GRADE framework. Heterogeneity among studies was quantified with the I-squared statistic, and publication bias was probed with both Egger’s and Begg’s tests. Crucially, the team went beyond simple pooled estimates: they computed ninety-five percent prediction intervals, which indicate the range of effects that might plausibly be expected in a future study conducted in a new population, and they performed both linear and non-linear dose–response meta-analyses to test whether longer durations of hormone use translated into progressively altered risk. This layered approach matters because a pooled relative risk alone can mask enormous variability in what individual studies actually find.

The headline result for oral contraceptives was, in statistical terms, a null finding. Across twenty studies, women who had used the pill showed a pooled relative risk of pancreatic cancer of 0.99, with a ninety-five percent confidence interval spanning 0.86 to 1.14 — a range that comfortably includes no effect. The prediction interval was strikingly wide, stretching from 0.62 to 1.59, and heterogeneity between studies was substantial at 61.4 percent. The GRADE assessment rated this evidence as very low certainty. In plain language, the analysis found no overall association between oral contraceptive use and pancreatic cancer, but the underlying studies disagreed with one another enough that the true effect in any given population could conceivably fall anywhere between a meaningful reduction and a meaningful increase in risk.

Menopausal hormone therapy told a similar story. Drawing on eighteen studies, the pooled adjusted relative risk was 0.92, with a confidence interval of 0.79 to 1.06 that again crossed the threshold of no effect. Heterogeneity was even higher here, at 75.9 percent, and the prediction interval ranged from 0.54 to 1.56, once more signaling that results varied dramatically across populations and study designs. Estrogen therapy used alone, examined across six studies, yielded a pooled relative risk of 0.82 with a confidence interval of 0.63 to 1.07 — a point estimate hinting at a possible protective trend, but one that failed to reach statistical significance and was likewise graded as very-low-certainty evidence. For all three of these exposures, the adjusted analyses simply did not support a consistent link with pancreatic cancer.

The one exception emerged with estrogen–progestin therapy, the combined form of menopausal hormone therapy in which estrogen is paired with a progestin to protect the uterine lining. Across five studies, this regimen was associated with a modest but statistically robust inverse association: a pooled relative risk of 0.85, with a tight confidence interval of 0.78 to 0.93 and, remarkably, zero heterogeneity among the contributing studies. The prediction interval of 0.77 to 0.94 mirrored that consistency. This was the only finding in the adjusted analyses to achieve statistical significance, and it was graded as low-certainty evidence — a notch above the very-low ratings given to the other exposures, but still short of the certainty clinicians would want before drawing firm conclusions.

The biology behind such a signal is not far-fetched. Pancreatic ductal adenocarcinoma, the dominant form of the disease, expresses estrogen receptors and the G protein-coupled estrogen receptor, and experimental work has implicated estrogen signaling in pathways central to cancer cell behavior, including the PI3K/AKT and MAPK cascades, insulin-like growth factor signaling, and inflammatory and oxidative stress processes. Progestins, meanwhile, can modulate cell proliferation and differentiation. A modest protective effect of combined estrogen–progestin therapy is therefore biologically plausible, even if the observational nature of the evidence and the small number of contributing studies demand caution. Confounding by indication, differences in body mass index, smoking status, diabetes prevalence and other lifestyle factors across study populations could all shape the observed associations in ways that statistical adjustment cannot fully remove.

Indeed, the secondary crude analyses illustrated exactly how fragile such associations can be. When the researchers pooled unadjusted effect estimates instead of adjusted ones, they found substantially lower odds of pancreatic cancer among oral contraceptive users (an odds ratio of 0.70) and estrogen–progestin users (an odds ratio of 0.55). But both of these crude analyses were plagued by substantial heterogeneity and wide prediction intervals — the estrogen–progestin prediction interval stretched from 0.16 to 1.97 — suggesting that the apparent protection in crude data may partly reflect confounding by factors such as socioeconomic status, healthcare access, or healthier baseline profiles among hormone users rather than a genuine biological effect. The divergence between crude and adjusted results is a textbook demonstration of why observational hormone epidemiology is so treacherous.

The dose–response analyses added a further layer of nuance. Neither oral contraceptive use nor menopausal hormone therapy showed a significant linear relationship with pancreatic cancer risk per five-year increase in duration of use: the relative risks were 1.07 (p = 0.158) for the pill and 0.84 (p = 0.128) for menopausal hormone therapy. Non-linear models likewise failed to identify any significant threshold or U-shaped pattern. In other words, there was no evidence that taking hormones for longer periods progressively shifted risk in either direction, which weakens the case for a strong causal relationship and suggests that any real effects, if they exist, are likely to be modest and context-dependent.

The authors’ conclusions are measured and appropriately cautious. The adjusted evidence did not show a consistent association between oral contraceptive, menopausal hormone therapy, or estrogen therapy use and pancreatic cancer risk, and although estrogen–progestin therapy was linked to a modest reduction in risk, that finding rests on low-certainty observational evidence from only five studies. The wide prediction intervals for oral contraceptives and menopausal hormone therapy indicate that associations may vary across populations and settings, and the team explicitly calls for further large prospective studies to clarify the long-term hormonal effects on pancreatic carcinogenesis. For the millions of women weighing the risks and benefits of hormonal medications, the practical takeaway is largely reassuring: nothing in this comprehensive synthesis suggests that these widely used therapies meaningfully raise the risk of pancreatic cancer. And for researchers, the modest inverse signal from combined therapy offers a tantalizing, testable hypothesis — one that could ultimately illuminate how estrogen and progestin signaling shapes one of medicine’s most lethal tumors.

Subject of Research: The association between oral contraceptive and menopausal hormone therapy use and pancreatic cancer risk

Article Title: Oral contraceptive and menopausal hormone therapy use and risk of pancreatic cancer: a systematic review, meta-analysis, and dose–response analysis

Article References: Oral contraceptive and menopausal hormone therapy use and risk of pancreatic cancer: a systematic review, meta-analysis, and dose–response analysis. (n.d.). https://doi.org/10.1186/s12885-026-16902-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16902-6

Keywords: pancreatic cancer, oral contraceptives, menopausal hormone therapy, estrogen therapy, estrogen–progestin therapy, meta-analysis, systematic review, dose–response analysis, observational studies, exogenous hormones, BMC Cancer, cancer epidemiology

The analysis of Disability-Adjusted Life Years (DALYs), a critical metric combining years of life lost due to premature death and years lived with disability, reveals a staggering increase in the burden of pancreatic cancer over the past three decades. In 1990, PC was responsible for approximately 1.76 million DALYs globally. By 2021, this figure more than doubled, reaching 4.25 million DALYs—a 141.48% surge that underscores the growing challenge posed by this lethal disease. Importantly, the age-standardized DALY rate increased by 11.57% to 48.71 per 100,000 population, adjusting for demographic changes and rising population age profiles.

Regional disparities are pronounced in these global statistics. The highest burden of pancreatic cancer, when measured by age-standardized DALY rates, is found predominantly in regions with high Socio-Demographic Index (SDI) scores—composite indicators reflecting income per capita, educational attainment, and fertility rates. High SDI countries, often representing developed nations, show elevated absolute burdens. However, the most alarming data emerge from transitional and developing economies, where age-standardized rates surpass both high and low SDI regions in many cases. These trends suggest that economic development alone does not confer protection; rather, complex interactions involving lifestyle, healthcare infrastructure, and environmental exposures influence the risk landscape.

This global inequality in pancreatic cancer burden is further quantified using sophisticated epidemiological tools. The Concentration Index (CI), which measures relative health inequalities linked to income, alongside the Slope Index of Inequality (SII), depicting absolute socioeconomic gaps, both demonstrate widening disparities. Between 1990 and 2021, the SII ballooned from 189.63 to 321.17 DALYs per 100,000 population. Such an alarming increase signifies that not only are disparities becoming more pronounced, but absolute gaps in pancreatic cancer burden between the richest and poorest populations are expanding, with low-income countries disproportionately affected.

Underlying these troubling patterns is the rising prevalence of modifiable risk factors intricately linked to pancreatic cancer development. Obesity and high fasting plasma glucose—commonly associated with type 2 diabetes—feature prominently among these risks. Both conditions have seen global increases parallel to the economic and nutritional transitions occurring across many regions. The pathogenic pathways whereby obesity and hyperglycemia facilitate carcinogenesis involve chronic systemic inflammation, insulin resistance, and metabolic dysregulation, which in turn promote tumor initiation and progression in pancreatic tissue.

Methodologically, the GBD 2021 study employs rigorous data synthesis and statistical modeling to estimate DALYs attributable to pancreatic cancer. Its inclusion of multifaceted variables such as age, sex, SDI, and exposure to major risk factors allows nuanced insights into epidemiologic trends and risk distributions. Visualization techniques, including age-sex pyramids and geographical maps, illustrate the diverse burden profiles and highlight hotspots requiring targeted interventions. This multifactorial approach transcends simplistic incidence counts, providing a deeper understanding of the disease’s societal and economic impact.

The observed slopes in increasing DALYs, particularly in transitional economies, may partly reflect improvements in cancer diagnosis and reporting, yet they simultaneously underscore a failure to control underlying risk factors or provide equitable access to healthcare services. Early detection of pancreatic cancer remains notoriously difficult due to subtle and nonspecific symptoms, contributing to late-stage diagnoses and poor prognosis. Consequently, delays in diagnosis are an important driver of both DALYs and mortality, suggesting a critical need for health system strengthening focused on awareness, screening, and early intervention.

Healthcare disparities further compound the crisis. Countries with lower SDI not only face higher burdens of disease but also contend with insufficient healthcare infrastructure, limited access to advanced diagnostics, and scarce availability of effective treatments, such as surgical resection and novel chemotherapeutic regimens. These limitations exacerbate the clinical outcomes gap between high- and low-income regions, translating into higher case-fatality rates and greater disability.

In addressing pancreatic cancer’s global burden, the study advocates for integrating preventive strategies that target modifiable risk factors before disease onset. Prioritizing obesity reduction, promoting metabolic health, and controlling diabetes through lifestyle interventions and public health policies can attenuate the rising trend. Moreover, investment in healthcare infrastructure, particularly in low SDI settings, is essential to improve early detection capabilities and ensure equitable treatment access.

International collaboration emerges as a cornerstone for success. Sharing epidemiological data, research breakthroughs, and best practices across borders can accelerate improvements in pancreatic cancer management globally. Collaborative efforts can also help establish standardized screening protocols, refine risk stratification tools, and develop culturally sensitive prevention campaigns that resonate with diverse populations.

Emerging technologies in diagnostic imaging and biomarker discovery hold promise to revolutionize pancreatic cancer detection. Liquid biopsies, molecular profiling, and artificial intelligence-driven image analysis may enable earlier and more precise diagnosis, thereby improving survival outcomes. However, the equitable deployment of such innovations remains a challenge, especially in resource-poor settings, reinforcing the necessity for capacity building and technology transfer.

Finally, the research highlights a pressing imperative: data systems must be enhanced worldwide to capture accurate, timely, and granular health information. Robust surveillance mechanisms are critical for monitoring epidemiological shifts, evaluating intervention efficacy, and informing policymaking. Without reliable data, efforts to mitigate pancreatic cancer’s burden may falter, perpetuating disparities and escalating costs to individuals and societies.

In summary, pancreatic cancer continues to pose a formidable global health threat, with its burden escalating sharply over recent decades and leading to increasingly stark socioeconomic and geographic inequalities. The convergence of rising risk factors, healthcare inequities, and diagnostic challenges underscores the urgency for a multi-pronged response encompassing public health interventions, healthcare improvements, and international cooperation. Without concerted action, the mortality and suffering caused by pancreatic cancer will intensify, frustrating progress toward global cancer control goals.

The findings from the 2021 GBD study serve as a vital call to the global medical and public health communities. They emphasize that pancreatic cancer’s fight is far from over and that addressing this silent killer requires addressing social determinants, reinforcing healthcare systems, and focusing on prevention alongside innovation. Through informed policies and collective will, the tide of pancreatic cancer’s devastation may yet be reversed.

Subject of Research: Global disparities and the burden of pancreatic cancer from 1990 to 2021, focusing on epidemiological trends, socioeconomic inequalities, and associated risk factors.

Article Title: Global disparities in the burden of pancreatic cancer (1990–2021): insights from the 2021 Global Burden of Disease study

Article References:
Liu, W., Rao, L., Qiao, Z. et al. Global disparities in the burden of pancreatic cancer (1990–2021): insights from the 2021 Global Burden of Disease study. BMC Cancer 25, 722 (2025). https://doi.org/10.1186/s12885-025-14110-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14110-2